2 active not recruiting, 1 not yet recruiting. 3 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Active not recruiting 2, Not yet recruiting 1 |
Follow Yusuf Menda: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of 212Pb-Pentixather Radioligand Therapy 212-Lead Pentixather, 203-Lead Pentixather SPECT/CT - Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung | Early Phase 1 | Not yet recruiting | Yusuf Menda | 20 | 2026-07-01 | 2025-07-08 |
| A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent [203Pb]VMT-α-NET, SPECT/CT - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 | Early Phase 1 | Active not recruiting | Yusuf Menda | 20 | 2022-08-22 | 2025-07-14 |
| Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors [68Ga]Pentixafor - Neuroendocrine Tumors | Early Phase 1 | Active not recruiting | Yusuf Menda | 30 | 2017-11-03 | 2025-07-14 |
Neuroendocrine Tumors (1) · Small Cell Lung Carcinoma (1)
68Ga-pentixafor (1) · Single Photon Emission Computed Tomography Computed Tomography (1)
United States (3)
P50CA174521 (1), P50CA302572 (1), R01CA243014 (1)